| Extrapyramidal side-effects of antipsychotics in a randomised trial |
British Journal of Psychiatry (subscription), UK - 1 hour ago
Email: del-miller{at}uiowa.edu AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, Forest Pharmaceuticals Inc, Janssen Pharmaceutica, Eli Lilly & Co, ...
|
| Prasugrel Decision Delayed; No Reason Why |
PharmExec.com, NJ - 1 hour ago
In a letter, Funtleyder said that the delay gives Bristol-Myers Squibb and Sanofi-Aventis’ Plavix more time to rule the roost. Lilly’s prasugrel, to be ...
|
| ImClone's Other Partner Pipes Up |
Forbes, NY - 2 hours ago
The news from Merck could be exactly what shareholders of ImClone's other marketing partner, Bristol-Myers Squibb (nyse: BMY - news - people ), wanted to ...
|
| Drugmakers see mixed results for shares in Q3 |
CNNMoney.com - 2 hours ago
Bristol-Myers Squibb Co. saw shares edge up just 1.6 percent, to $20.85. Merck & Co. and Schering-Plough Corp., partners on cholesterol drugs including ...
|
| Sector Snap: Biotechnology |
Forbes, NY - 2 hours ago
... came for New York-based ImClone Systems Inc., which gained 54 percent over the quarter as it was courted by cancer drug partner Bristol-Myers Squibb Co. ...
|
| Erbitux, Radiation Improve Head and Neck Cancer Survival |
FDA news (subscription), VA - 3 hours ago
... Erbitux and radiation therapy survived for at least five years in a Phase III clinical trial, according to Bristol-Myers Squibb and ImClone Systems. ...
|
| Health Winners & Losers: ImClone |
TheStreet.com - 3 hours ago
Shares of Bristol-Myers Squibb(BMY Quote - Cramer on BMY - Stock Picks), which last week announced a hostile tender for ImClone's shares at $62 a share, ...
|
